{"version":"1.0","provider_name":"Canadian Drug Policy Coalition","provider_url":"https:\/\/www.drugpolicy.ca\/fr\/","author_name":"Canadian Drug Policy Coalition","author_url":"https:\/\/www.drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/","title":"Intimate partner violence, substance use, and COVID-19 - Canadian Drug Policy Coalition","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"2mgbWi8NKk\"><a href=\"https:\/\/www.drugpolicy.ca\/fr\/intimate-partner-violence-substance-use-and-covid-19\/\">Intimate partner violence, substance use, and COVID-19<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.drugpolicy.ca\/fr\/intimate-partner-violence-substance-use-and-covid-19\/embed\/#?secret=2mgbWi8NKk\" width=\"600\" height=\"338\" title=\"&#8220;Intimate partner violence, substance use, and COVID-19&#8221; &#8212; Canadian Drug Policy Coalition\" data-secret=\"2mgbWi8NKk\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.drugpolicy.ca\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/04\/Screen-Shot-2021-04-20-at-5.43.40-PM.png","thumbnail_width":848,"thumbnail_height":536,"description":"CCSA: \"During COVID-19 and its aftermath it is important to consider the impacts of the pandemic and social and physical isolation on women\u2019s health. This sheet explores adaptations to practice for service organizations and frontline workers, to respond to concerning trends in intimate partner violence (IPV) and substance use in the COVID-19 context.\""}